MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/jcm14248918

Медицинская библиотека · Journal of clinical medicine · 2025

Drug Persistence of Patients with Inflammatory Bowel Disease Under Biological Treatment in the Pre IL-23 Era in a Tertiary Referral Center in Germany.

Farrag Karima, Grimm Lars, Dahmer Iulia, Stratmann Katharina, Dienethal Antje, Sprinzl Kathrin, Lande Raul, Zeuzem Stefan, Blumenstein Irina, Kubesch Alica

СтатьяПеревод пока не подготовлен

Аннотация

Background/

Objectives

Predicting treatment persistence in inflammatory bowel disease (IBD) remains challenging despite a broadened therapeutic arsenal. This study used longitudinal data to assess drug persistence across four biologics for IBD prior to Interleukin (IL)-23 blocker approval.

Methods

We retrospectively analyzed IBD outpatients at Goethe University Hospital. Laboratory data and treatment adherence were collected to determine how many patients continued each biological therapy after induction and at 1 year.

Results

Of 587 patients, those on azathioprine or mercaptopurine were excluded (focusing on biologics). Four biologicals were analyzed: 280 patients received one of them; 312 (53.2%) had Crohn's disease and 275 (46.8%) had Ulcerative Colitis. Infliximab (IFX) was given to 93 patients (median 912 days; range 20-5273); at endpoint, 39 (42.4%) remained on IFX. Adalimumab (ADA) was used by 165 patients (median 1051 days; range 48-4458); 87 (52.4%) remained at endpoint. Vedolizumab (VDZ) included 116 patients (median 717 days; range 0-2204); 75 (64.4%) remained at endpoint. Ustekinumab (UST) was given to 62 patients (median 660 days; range 50-1399); 51 (83.6%) remained at endpoint. Some patients were exposed to multiple biologicals, contributing to smaller numbers for newer drugs. When evaluated as a first-line biological, UST (median 787 days) and VDZ (median 756.5 days) had the shortest durations, while TNF-α blockers (ADA, IFX) showed the greatest resistance as first-line therapy.

Conclusions

Most patients stayed on their initial therapy after induction and at 1 year. These findings support the sustained use of established biological therapies as cost-effective, steroid-sparing options even after IL-23 approval and may inform patient counseling and long-term pharmacoeconomic considerations.

Для цитирования: Farrag Karima, Grimm Lars, Dahmer Iulia, Stratmann Katharina, Dienethal Antje, Sprinzl Kathrin, Lande Raul, Zeuzem Stefan, Blumenstein Irina, Kubesch Alica. Drug Persistence of Patients with Inflammatory Bowel Disease Under Biological Treatment in the Pre IL-23 Era in a Tertiary Referral Center in Germany.. Journal of clinical medicine. 2025. DOI: 10.3390/jcm14248918.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.